Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Coronary flow velocity reserve is impaired in hypertensive patients with hyperhomocysteinemia

Journal of Human Hypertension volume 28, pages 743–747 (2014)Cite this article

Subjects

Abstract

Hyperhomocysteinemia (HHcy) is an independent risk factor for coronary artery disease. Chronic HHcy induces coronary endothelial injury, and homocysteine (Hcy) inhibits insulin sensitivity by inducing endoplasmic reticulum stress in adipose tissue. However, the combined effects of chronic HHcy and hypertension on coronary artery endothelial function have still remained unclear. Fifty-one patients with essential hypertension (HT) were recruited, and were divided into nHT group (without HHcy) and H-type HT group (with HHcy). Forty healthy subjects were enrolled as controls. We assessed coronary artery endothelial function by coronary flow velocity reserve (CFVR). Hcy levels were significantly higher (15.60±6.58 vs 13.08±4.13 μmol l−1, P<0.05), whereas CFVR values were significantly lower in the HT patients than in the control group (2.88±0.70 vs 3.23±0.54, P<0.05). Hcy levels were negatively correlated with CFVR value (r=−0.578, P<0.01, 95% confidence interval −0.085 to −0.046). The homeostasis model assessment-insulin resistance values were significantly higher (3.92±2.16 vs 2.72±1.50, P<0.05) , whereas CFVR values were significantly lower in H-type HT group than in nHT group (2.31±0.31 vs 3.25±0.62, P<0.01). Coronary artery endothelial function may be impaired in essential hypertensive patients with HHcy, and insulin resistance induced by HHcy may contribute to this damage.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. New Engl J Med 1991; 324 (17): 1149–1155.

    Article  CAS  PubMed  Google Scholar 

  2. Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011; 58 (10): 1025–1033.

    Article  CAS  PubMed  Google Scholar 

  3. Wang G, Dai J, Mao J, Zeng X, Yang X, Wang X . Folic acid reverses hyper-responsiveness of LPS-induced chemokine secretion from monocytes in patients with hyperhomocysteinemia. Atherosclerosis 2005; 179 (2): 395–402.

    Article  CAS  PubMed  Google Scholar 

  4. Wang G, Mao JM, Wang X, Zhang FC . Effect of homocysteine on plaque formation and oxidative stress in patients with acute coronary syndromes. Chin Med J (Engl) 2004; 117 (11): 1650–1654.

    CAS  Google Scholar 

  5. He L, Zeng H, Li F, Feng J, Liu S, Liu J et al. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab 2010; 299 (6): E1061–E1065.

    Article  CAS  PubMed  Google Scholar 

  6. Li Y, Zhang H, Jiang C, Xu M, Pang Y, Feng J et al. Hyperhomocysteinemia promotes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue. J Biol Chem 2013; 288 (14): 9583–9592.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Shimbo D, Muntner P, Mann D, Viera AJ, Homma S, Polak JF et al. Endothelial dysfunction and the risk of hypertension: the multi-ethnic study of atherosclerosis. Hypertension 2010; 55 (5): 1210–1216.

    Article  CAS  PubMed  Google Scholar 

  8. Gupta V, Sachdeva S, Khan AS, Haque SF . Endothelial dysfunction and inflammation in different stages of essential hypertension. Saudi J Kidney Dis Transpl 2011; 22 (1): 97–103.

    PubMed  Google Scholar 

  9. Schulz E, Gori T, Munzel T . Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 2011; 34 (6): 665–673.

    Article  CAS  PubMed  Google Scholar 

  10. Wang G, Woo CW, Sung FL, Siow YL, O K . Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. Arterioscler Thromb Vasc Biol 2002; 22 (11): 1777–1783.

    Article  CAS  PubMed  Google Scholar 

  11. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW . Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001; 103 (22): 2717–2723.

    Article  CAS  PubMed  Google Scholar 

  12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42 (6): 1206–1252.

    Article  CAS  PubMed  Google Scholar 

  13. Matsumura Y, Hozumi T, Watanabe H, Fujimoto K, Sugioka K, Takemoto Y et al. Cut-off value of coronary flow velocity reserve by transthoracic Doppler echocardiography for diagnosis of significant left anterior descending artery stenosis in patients with coronary risk factors. Am J Cardiol 2003; 92 (12): 1389–1393.

    Article  PubMed  Google Scholar 

  14. Pizzuto F, Voci P, Mariano E, Puddu PE, Chiavari PA, Romeo F . Noninvasive coronary flow reserve assessed by transthoracic coronary Doppler ultrasound in patients with left anterior descending coronary artery stents. Am J Cardiol 2003; 91 (5): 522–526.

    Article  PubMed  Google Scholar 

  15. Yan TT, Li Q, Zhang XH, Wu WK, Sun J, Li L et al. Homocysteine impaired endothelial function through compromised vascular endothelial growth factor/Akt/endothelial nitric oxide synthase signalling. Clin Exp Pharmacol Physiol 2010; 37 (11): 1071–1077.

    Article  CAS  PubMed  Google Scholar 

  16. Dhillon B, Badiwala MV, Maitland A, Rao V, Li SH, Verma S . Tetrahydrobiopterin attenuates homocysteine induced endothelial dysfunction. Mol Cell Biochem 2003; 247 (1-2): 223–227.

    Article  CAS  PubMed  Google Scholar 

  17. Suematsu N, Ojaimi C, Kinugawa S, Wang Z, Xu X, Koller A et al. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation 2007; 115 (2): 255–262.

    Article  CAS  PubMed  Google Scholar 

  18. Wang D, Wang H, Luo P, Hwang A, Sun D, Wang Y et al. Effects of ghrelin on homocysteine-induced dysfunction and inflammatory response in rat cardiac microvascular endothelial cells. Cell Biol Int 2012; 36 (6): 511–517.

    Article  CAS  PubMed  Google Scholar 

  19. Edirimanne VE, Woo CW, Siow YL, Pierce GN, Xie JY, O K . Homocysteine stimulates NADPH oxidase-mediated superoxide production leading to endothelial dysfunction in rats. Can J Physiol Pharmacol 2007; 85 (12): 1236–1247.

    Article  CAS  PubMed  Google Scholar 

  20. Ji C, Kaplowitz N . Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J Gastroenterol 2004; 10 (12): 1699–1708.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Chiang JK, Sung ML, Yu HR, Chang HI, Kuo HC, Tsai TC et al. Homocysteine induces smooth muscle cell proliferation through differential regulation of cyclins A and D1 expression. J Cell Physiol 2011; 226 (4): 1017–1026.

    Article  CAS  PubMed  Google Scholar 

  22. Rajkumar V, Ragatzki P, Sima A, Levy J . Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions: implications for therapy. Endocrine 1999; 11 (1): 57–60.

    Article  CAS  PubMed  Google Scholar 

  23. Vignini A, Nanetti L, Bacchetti T, Ferretti G, Curatola G, Mazzanti L . Modification induced by homocysteine and low-density lipoprotein on human aortic endothelial cells: an in vitro study. J Clin Endocrinol Metab 2004; 89 (9): 4558–4561.

    Article  CAS  PubMed  Google Scholar 

  24. Tousoulis D, Bouras G, Antoniades C, Marinou K, Papageorgiou N, Miliou A et al. Methionine-induced homocysteinemia impairs endothelial function in hypertensives: the role of asymmetrical dimethylarginine and antioxidant vitamins. Am J Hypertens 2011; 24 (8): 936–942.

    Article  CAS  PubMed  Google Scholar 

  25. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 2001; 24 (3): 533–538.

    Article  CAS  PubMed  Google Scholar 

  26. Golbahar J, Aminzadeh MA, Kassab SE, Omrani GR . Hyperhomocysteinemia induces insulin resistance in male Sprague-Dawley rats. Diabetes Res Clin Pract 2007; 76 (1): 1–5.

    Article  CAS  PubMed  Google Scholar 

  27. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP . Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000; 23 (12): 1816–1822.

    Article  CAS  PubMed  Google Scholar 

  28. Li Y, Jiang C, Xu G, Wang N, Zhu Y, Tang C et al. Homocysteine upregulates resistin production from adipocytes in vivo and in vitro. Diabetes 2008; 57 (4): 817–827.

    Article  CAS  PubMed  Google Scholar 

  29. Najib S, Sanchez-Margalet V . Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J Mol Endocrinol 2001; 27 (1): 85–91.

    Article  CAS  PubMed  Google Scholar 

  30. Montagnani M, Chen H, Barr VA, Quon MJ . Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001; 276 (32): 30392–30398.

    Article  CAS  PubMed  Google Scholar 

  31. Taniguchi CM, Emanuelli B, Kahn CR . Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7 (2): 85–96.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Major National Basic Research Program of P.R. China (No. 2011CB503904) and the Chinese National Natural Science Foundation (No. 81270369, 81070244) to Guang Wang. We thank the NIH Fellows Editorial Board for modifying our manuscript.

Author information

Author notes

  1. J Liu and Y Xu: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Endocrinology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, People’s Republic of China

    J Liu, Y Xu, H Zhang, X Gao, H Fan & G Wang

Authors
  1. J Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Wang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, J., Xu, Y., Zhang, H. et al. Coronary flow velocity reserve is impaired in hypertensive patients with hyperhomocysteinemia. J Hum Hypertens 28, 743–747 (2014). https://doi.org/10.1038/jhh.2014.22

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2014.22

This article is cited by

Search

Advanced search

Quick links